Metformin received increasing attention due to its potential antiproliferative properties since Evans et al. 5 showed decreased cancer incidence in individuals with type-2 diabetes taking metformin, compared with patients under sulfonylureas or exogenous insulin treatments, which, on the other hand, also showed increased cancer-related mortality6. Here, INS is linked to cancer.